THERAPIES
-
The 10 key takeaways from CHS advocacy efforts to obtain access to emicizumab (Hemlibra)
by David Page, CHS National Director of Health Policy The Canadian Hemophilia Society (CHS), its chapters and members have expended great efforts to advocate for...
-
Update on products in the pipeline
Updated charts for products in the pipeline have been uploaded on the CHS website. The CHS publishes four charts, one each for clotting factor concentrates, inhibitor...
-
Update on access to coagulation products for hemophilia A and B
by David Page, CHS National Director of Health Policy Access to a wide range of coagulation products is expanding in the provinces and territories served by...
-
All About Mild Hemophilia
Mild hemophilia can be very serious and even life-threatening if injuries or bleeds are not treated promptly and adequately. The past few years, a lot...
-
Has the bleeding disorder world fundamentally changed?
by David Page, CHS National Director of Health Policy Given recent advances in therapies for inherited bleeding disorders, especially hemophilia A and B, I have...